when designing a chimeric antigen receptor for cart t cell therapy can't we use a target which is also exist in T cells but express excessively in cancerous cells?
Dear Merium Fernando ,
Theoretically, it should be possible. However, I think it is quite difficult to tweak a CAR's affinity to completely avoid fratricide. Here are two articles with different approaches to get you going. Drent et al. try to lower the affinity against CD38 (against multiple myeloma, but also expressed on activated T cells) through light chain exchange (LCE). Kim et al. knock out CD33 in HSC prior to transplant and anti-CD33 CAR-T cell therapy against AML to avoid killing of the the HSCs. Hope this helps.
Best wishes, Gils
Article A Rational Strategy for Reducing On-Target Off-Tumor Effects...
Article Genetic Inactivation of CD33 in Hematopoietic Stem Cells to ...
- Badges
- Science topic
- Similar topics
- Medicine
- Oncology
- Cancer Research
- Cancer Biology
- Cancer Cells